New stock news: Ke Li Port stock IPO prospectus invalid.
KeLi Limited Company (referred to as "KeLi")'s Hong Kong stock prospectus submitted on December 18, 2025, expired after 6 months on June 18, 2026.
Koli Corporation Limited (referred to as Koli) submitted its Hong Kong stock prospectus on December 18, 2025, which expired after 6 months on June 18, 2026, with CICC as its exclusive sponsor at the time of submission.
According to the prospectus, Koli is a comprehensive medical health solution provider originating from South Korea, with its main business located in China and expanding internationally. According to data from Frost & Sullivan, based on revenue in 2024, the company ranks among the top ten in marketing, promotion, and sales markets within China Meheco Group. Based on revenue in 2024, the company is the largest pediatric pharmaceutical marketing, promotion, and sales service provider in China, accounting for approximately 15.9% of the market share in China.
Related Articles
China Securities Co., Ltd.: After a short-term rebound, A shares may fluctuate. AI computing power remains the main trend in the medium to long term.
AMASSE CAPITAL (08168): Shareholders demand the removal of current directors.
CITIC SEC: Rate hikes difficult to shake AI valuation, non-AI weakness needs to break through its own narrative.
China Securities Co., Ltd.: After a short-term rebound, A shares may fluctuate. AI computing power remains the main trend in the medium to long term.
AMASSE CAPITAL (08168): Shareholders demand the removal of current directors.
CITIC SEC: Rate hikes difficult to shake AI valuation, non-AI weakness needs to break through its own narrative.
RECOMMEND
